Cover Image
市場調查報告書

Hydra Biosciences, Inc. : 產品平台分析

Hydra Biosciences, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 226213
出版日期 內容資訊 英文 30 Pages
訂單完成後即時交付
價格
Back to Top
Hydra Biosciences, Inc. : 產品平台分析 Hydra Biosciences, Inc. - Product Pipeline Review - 2015
出版日期: 2015年08月12日 內容資訊: 英文 30 Pages
簡介

Hydra Biosciences, Inc.是以美國麻薩諸塞州為據點,使用獨家的離子通道開發劃時代藥劑的生物製藥公司。該公司提供疼痛,發炎,腎臟疾病,神經不安症,肺部疾病等領域的治療藥。

本報告提供Hydra Biosciences, Inc.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Hydra Biosciences, Inc.的基本資料

  • Hydra Biosciences, Inc.概要
  • 主要資訊
  • 企業資料

Hydra Biosciences, Inc.:R&D概要

  • 主要的治療範圍

Hydra Biosciences, Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Hydra Biosciences, Inc.:開發中產品概況

  • 初期階段的開發中產品
  • IND/CTA 所申請的產品/聯合治療模式
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Hydra Biosciences, Inc.:藥物簡介

  • HC-030031
  • HC-067047
  • Small Molecules to Antagonize TRPV3 for Pruritus and Psoriasis
  • Small Molecules to Block CatSper1 Ion Channel for Contraception
  • Small Molecules to Antagonize TRP for Renal Diseases and Disorders

Hydra Biosciences, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Hydra Biosciences, Inc.:最近的開發平台趨勢

Hydra Biosciences, Inc.:暫停中的計劃

Hydra Biosciences, Inc.:開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • HC-030031

Hydra Biosciences, Inc.:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07487CDB

Summary

Global Markets Direct's, 'Hydra Biosciences, Inc. - Product Pipeline Review - 2015', provides an overview of the Hydra Biosciences, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Hydra Biosciences, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Hydra Biosciences, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Hydra Biosciences, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Hydra Biosciences, Inc.'s pipeline products

Reasons to buy

  • Evaluate Hydra Biosciences, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Hydra Biosciences, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Hydra Biosciences, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Hydra Biosciences, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Hydra Biosciences, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Hydra Biosciences, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Hydra Biosciences, Inc. Snapshot
    • Hydra Biosciences, Inc. Overview
    • Key Information
    • Key Facts
  • Hydra Biosciences, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Hydra Biosciences, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Hydra Biosciences, Inc. - Pipeline Products Glance
    • Hydra Biosciences, Inc. - Early Stage Pipeline Products
      • IND/CTA Filed Products/Combination Treatment Modalities
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Hydra Biosciences, Inc. - Drug Profiles
    • HC-030031
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HC-067047
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Antagonize TRPV3 for Pruritus and Psoriasis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Block CatSper1 Ion Channel for Contraception
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Antagonize TRP for Renal Diseases and Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Hydra Biosciences, Inc. - Pipeline Analysis
    • Hydra Biosciences, Inc. - Pipeline Products by Target
    • Hydra Biosciences, Inc. - Pipeline Products by Route of Administration
    • Hydra Biosciences, Inc. - Pipeline Products by Molecule Type
    • Hydra Biosciences, Inc. - Pipeline Products by Mechanism of Action
  • Hydra Biosciences, Inc. - Recent Pipeline Updates
  • Hydra Biosciences, Inc. - Dormant Projects
  • Hydra Biosciences, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • HC-030031
  • Hydra Biosciences, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Hydra Biosciences, Inc., Key Information
  • Hydra Biosciences, Inc., Key Facts
  • Hydra Biosciences, Inc. - Pipeline by Indication, 2015
  • Hydra Biosciences, Inc. - Pipeline by Stage of Development, 2015
  • Hydra Biosciences, Inc. - Monotherapy Products in Pipeline, 2015
  • Hydra Biosciences, Inc. - Out-Licensed Products in Pipeline, 2015
  • Hydra Biosciences, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Hydra Biosciences, Inc. - IND/CTA Filed, 2015
  • Hydra Biosciences, Inc. - Preclinical, 2015
  • Hydra Biosciences, Inc. - Discovery, 2015
  • Hydra Biosciences, Inc. - Pipeline by Target, 2015
  • Hydra Biosciences, Inc. - Pipeline by Route of Administration, 2015
  • Hydra Biosciences, Inc. - Pipeline by Molecule Type, 2015
  • Hydra Biosciences, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Hydra Biosciences, Inc. - Recent Pipeline Updates, 2015
  • Hydra Biosciences, Inc. - Dormant Developmental Projects,2015
  • Hydra Biosciences, Inc. - Discontinued Pipeline Products, 2015

List of Figures

  • Hydra Biosciences, Inc. - Pipeline by Top 10 Indication, 2015
  • Hydra Biosciences, Inc. - Pipeline by Stage of Development, 2015
  • Hydra Biosciences, Inc. - Monotherapy Products in Pipeline, 2015
  • Hydra Biosciences, Inc. - Pipeline by Top 10 Target, 2015
  • Hydra Biosciences, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Hydra Biosciences, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Hydra Biosciences, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top